Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension.

Bellaye PS, Yanagihara T, Granton E, Sato S, Shimbori C, Upagupta C, Imani J, Hambly N, Ask K, Gauldie J, Iglarz M, Kolb M.

Eur Respir J. 2018 Jul 5. pii: 1701857. doi: 10.1183/13993003.01857-2017. [Epub ahead of print] No abstract available.

PMID:
29976656
2.

Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition.

Zabini D, Granton E, Hu Y, Miranda MZ, Weichelt U, Breuils Bonnet S, Bonnet S, Morrell NW, Connelly KA, Provencher S, Ghanim B, Klepetko W, Olschewski A, Kapus A, Kuebler WM.

Am J Respir Crit Care Med. 2018 Jan 15;197(2):244-260. doi: 10.1164/rccm.201702-0386OC.

PMID:
29095649
3.

Pulmonary vascular changes 22 years after single lung transplantation for pulmonary arterial hypertension: a case report with molecular and pathological analysis.

Zhao YD, Peng J, Granton E, Lin K, Lu C, Wu L, Machuca T, Waddell TK, Keshavjee S, de Perrot M.

Pulm Circ. 2015 Dec;5(4):739-43. doi: 10.1086/683692.

4.

A Biochemical Approach to Understand the Pathogenesis of Advanced Pulmonary Arterial Hypertension: Metabolomic Profiles of Arginine, Sphingosine-1-Phosphate, and Heme of Human Lung.

Zhao YD, Chu L, Lin K, Granton E, Yin L, Peng J, Hsin M, Wu L, Yu A, Waddell T, Keshavjee S, Granton J, de Perrot M.

PLoS One. 2015 Aug 28;10(8):e0134958. doi: 10.1371/journal.pone.0134958. eCollection 2015.

Supplemental Content

Loading ...
Support Center